SUPERNUS PHARMACEUTICALS FKA SAGE THERAPEUTICS

Lobbying client · Massachusetts · filed 2025 to 2025

A clinical-stage biopharmaceutical company.

$200,000 Reported spend

4 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 4 filings. Everything on this page is grouped by the client's LDA id (193514), not by name.

Firms hired 1

W STRATEGIES, LLC $200,000 4 filings

Reported by year 1 year

2025 $200,000 4 filings

Issues lobbied 1

Health Issues 4

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Recent filings 4 total

4T

W STRATEGIES, LLC

4th Quarter (Oct 1 - Dec 31) 2025 · $50,000 income · posted Jan 20, 2026

View → Q3

W STRATEGIES, LLC

3rd Quarter (July 1 - Sep 30) 2025 · $50,000 income · posted Oct 20, 2025

View → Q2

W STRATEGIES, LLC

2nd Quarter (Apr 1 - June 30) 2025 · $50,000 income · posted Jul 18, 2025

View → Q1

W STRATEGIES, LLC

1st Quarter (Jan 1 - Mar 31) 2025 · $50,000 income · posted Apr 18, 2025

View →

Affiliated organisations 1

SUPERNUS PHARMACEUTICALS, INC. United States of America named on 1 filing

Section 6 of the LD-2: organisations that contribute to or take part in this client's lobbying.

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.